

February 21, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
--	--

Dear Sir/Madam,

Sub: Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Promoter of the Company

This is to inform you that, pursuant to the Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011, the Company has received disclosure from Mr. Narsimha Shibroor Kamath, Promoter of the Company regarding the acquisition of 77,000 shares and 23,000 shares of Bliss GVS Pharma Limited through the open market on February 18, 2025, and February 19, 2025, respectively.

This is for your information and record.

Thanking you.

Yours Faithfully,

For Bliss GVS Pharma Limited


Aditi Bhatt
Company Secretary



Encl: a/a

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory :

Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

February 20, 2025

To, Corporate Relationship Dept., BSE Limited , Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001. Scrip Code: 506197	To, Listing Department, National Stock Exchange of India Ltd. , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E). Mumbai-400 051 Symbol: BLISSGVS	To, Bliss GVS Pharma Limited 102, Hyde Park, Saki Vihar Road, Andheri (East). Mumbai - 400072.
---	---	---

Dear Sir/Madam,

Subject: Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Enclosed herewith is the disclosure as required in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time, regarding the acquisition of 77,000 shares and 23,000 shares of Bliss GVS Pharma Limited through the open market on February 18, 2025, and February 19, 2025, respectively.

Kindly acknowledge receipt of the same.

Thanking You,



Narsimha Shibroor Kamath
Promoter

Encl: a/a

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Bliss GVS Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer - Mr. Narsimha Shibroor Kamath Persons Acting in Concert (PAC) - Mrs. Shruti Vishal Rao Dr. Vibha Gagan Sharma Mr. Gagan Harsh Sharma Mr. Shibroor Gokuldas Kamath Mr. Ramadas Vasudev Kamath Ms. Punita Sharma Ramadas Vasudev Kamath HUF		
Whether the acquirer belongs to Promoter / Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	3,23,37,024	30.69%	NA
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
b) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL
e) Total (a+ b+ c+ d)	3,23,37,024	30.69%	NA
Details of acquisition / sale			
a) Shares carrying voting rights acquired / sold	1,00,000	0.09%	NA
b) VRs acquired / sold otherwise than by shares	NIL	NIL	NIL
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold	NIL	NIL	NIL
d) Shares encumbered/invoked / released by the acquirer	NIL	NIL	NIL
e) Total (a+ b+ c+/-d)	1,00,000	0.09%	NA

2. 20. 15

After the acquisition / sale, holding of:			
a) Shares carrying voting rights acquired	3,24,37,024	30.78%	NA
b) Shares encumbered with the acquirer	NIL	NIL	NIL
c) VRs otherwise than by shares	NIL	NIL	NIL
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
e) Total (a+b+c+d)	3,24,37,024	30.78%	NA
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	77,000 shares acquired on 18.02.2025 and 23,000 shares acquired on 19.02.2025		
* Equity share capital / total voting capital of the TC before the said acquisition /sale	Rs. 10,53,70,272/-		
* Equity share capital / total voting capital of the TC after the said acquisition /sale	Rs. 10,53,70,272/-		
Total diluted share/voting capital of the TC after the said acquisition	NA		

(*) Total share capital/ voting capital has been taken after considering listing & trading approval dated January 29, 2025, for the allotment of 4,000 equity shares under the Employee Stock Option Plan. This allotment occurred after the latest shareholding pattern was filed with the stock exchanges under Clause 35 of the Listing Agreement.

(**) Diluted share/voting capital means the total number of shares in TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



Signature of the acquirer
Narsimha Shibroor Kamath

Place: Mumbai

Date: February 20, 2025
